Ampersand Biomedicines has announced the acquisition of antibody discovery technology company AbCheck, previously a wholly-owned subsidiary of Affimed. Ampersand Biomedicines launched out of Flagship Pioneering in March 2023. The company hopes the addition of AbCheck’s discovery platform will enable cost-effective and strategic acceleration of its own Address, Navigate, Determine (AND) platform. Jason Gardner, CEO of […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!